Bradykinin receptor ligands: therapeutic perspectives

被引:0
|
作者
François Marceau
Domenico Regoli
机构
[1] Centre de Recherche,
[2] Centre Hospitalier Universitaire de Québec,undefined
[3] Pavillon L'Hôtel-Dieu de Québec,undefined
[4] 11 Côte-du-Palais,undefined
[5] Institute of Pharmacology,undefined
[6] Faculty of Medicine,undefined
[7] University of Ferrara,undefined
[8] Via F. di Mortara 19,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The kallikrein–kinin system consists of the precursor kininogens, the proteolytic kallikrein enzymes, the kinin peptides (which are produced through cleavage of kininogens by kallikreins) and two G-protein-coupled receptors (GPCRs), termed the B1 and B2 receptors, that mediate the biological effects of kinin peptides.The growing knowledge of the biological role of kinins has fuelled the development of potent and selective kinin receptor modulators as potential therapeutics.This medicinal chemistry effort, which was initiated with peptides in the 1970s, has now culminated in the production of a number of novel non-peptide antagonists, some of which are awaiting clinical trials.This article provides an overview of the kinin biology that is relevant to the roles of kinins in disease, and then considers the potential of kinin receptor modulators in various disease indications, including inflammation and pain.
引用
收藏
页码:845 / 852
页数:7
相关论文
共 50 条
  • [41] BRADYKININ RECEPTOR ANTAGONISTS
    BURCH, RM
    FARMER, SG
    STERANKA, LR
    MEDICINAL RESEARCH REVIEWS, 1990, 10 (02) : 237 - 269
  • [42] The therapeutic potential of histamine receptor ligands in inflammatory bowel disease
    Neumann, Detlef
    Seifert, Roland
    BIOCHEMICAL PHARMACOLOGY, 2014, 91 (01) : 12 - 17
  • [43] Adenosine receptor ligands: Potential as therapeutic agents in asthma and COPD
    Fozard, JR
    Hannon, JP
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 1999, 12 (02) : 111 - 114
  • [44] GALANIN RECEPTOR LIGANDS AS POTENTIAL THERAPEUTIC AGENTS IN DEPRESSION AND NEURODEGENERATION
    BARTFAI, T
    LANGEL, U
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1995, 30 : S163 - S174
  • [45] Design of nucleoside and nucleotide receptor ligands as potential therapeutic agents
    Jacobson, Kenneth A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [46] Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
    Cobos, E. J.
    Entrena, J. M.
    Nieto, F. R.
    Cendan, C. M.
    Del Pozo, E.
    CURRENT NEUROPHARMACOLOGY, 2008, 6 (04) : 344 - 366
  • [47] The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease
    Heitsch, H
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (05) : 759 - 770
  • [48] Bradykinin B2 Receptor Agonism: A Novel Therapeutic Strategy for Myocardial Infarction?
    Duchene, Johan
    Bader, Michael
    AMERICAN JOURNAL OF HYPERTENSION, 2010, 23 (05) : 459 - 459
  • [49] The B1 receptor of the bradykinin: potential therapeutic target for vascular hyperpermeability of sepsis
    Ruiz, S.
    Merlet-Dupuy, V.
    Buleon, M.
    Vardon, F.
    Conil, J-M
    Tack, I.
    Fourcade, O.
    Minville, V.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2014, 33 : A105 - A105
  • [50] Sigma-2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy
    Huang, Yun-Sheng
    Lu, He-Lin
    Zhang, Lang-Jun
    Wu, Zongwen
    MEDICINAL RESEARCH REVIEWS, 2014, 34 (03) : 532 - 566